SCHEMBL29375397

SCHEMBL29375397

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.52
REN P00797 2/20 0.52
EDNRA P25101 1/20 0.50
CASP1 P29466 1/20 0.49
CASP3 P42574 1/20 0.49
CASP4 P49662 1/20 0.49
CASP5 P51878 1/20 0.49
CASP7 P55210 1/20 0.49
CASP9 P55211 1/20 0.49
CASP6 P55212 1/20 0.49
CASP8 Q14790 1/20 0.49
CASP10 Q92851 1/20 0.49
MAGI3 Q5TCQ9 1/20 0.49
BACE1 P56817 1/20 0.48
CCKBR P32239 3/20 0.48
GHSR Q92847 1/20 0.47
OPRM1 P35372 2/20 0.47
OPRD1 P41143 2/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30054135 0.91 EDNRA (0.58) ACEEDNRACASP1CASP3CASP4
SCHEMBL30721568 0.87 EDNRA (0.60) EDNRACASP1CASP3CASP4CASP5
SCHEMBL29375915 0.86 OPRM1 (0.59) ACEEDNRAMAGI3GHSROPRM1
SCHEMBL30250470 0.85 CCKBR (0.53) RENBACE1CCKBROPRD1L3MBTL1
SCHEMBL30158459 0.84 OPRD1 (0.65) EDNRACCKBRGHSROPRM1OPRD1
SCHEMBL30166479 0.84 OPRM1 (0.56) ACEEDNRAMAGI3GHSROPRM1
SCHEMBL2193967 0.83 BACE1 (0.51) EDNRACASP1CASP3CASP4CASP5
SCHEMBL29706340 0.83 EDNRA (0.64) ACEEDNRAMAGI3KMT2AL3MBTL1
SCHEMBL29603769 0.83 ERAP2 (0.62) ACEEDNRAMAGI3KMT2AL3MBTL1
SCHEMBL30051856 0.83 ACE (0.61) ACEEDNRAMAGI3OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4146249-A1 IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE Neuland Laboratories Ltd (IN) 2023-03-15 EP disclosed
US-11396533-B2 Process for the manufacture of GLP-1 analogues Fresenius Kabi Ipsum S.R.L. (IT) 2022-07-26 US disclosed
US-20220041680-A1 PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES Fresenius Kabi Ipsum S.R.L. (IT) 2022-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041680-A1 PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES GLP1R, IAPP, VIP ACE 2382/4885REN 737/4885EDNRA 3658/4885
US-11396533-B2 Process for the manufacture of GLP-1 analogues GLP1R, IAPP, VIP ACE 2382/4885REN 737/4885EDNRA 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.